On March 1, 2018, MannKind (MNKD) released a PR announcing the start of a Phase 1 clinical trial with their PAH candidate. This study was to determine the safety, tolerability and pharmacokinetics for the Tre-t drug. Thereafter, on June 7th, 2018, the company announced the Phase 1 clinical trial had been completed and all milestones were successful for the study objectives.
Subsequent to this June 2018 data release, MannKind has promoted their Tre-t drug as being ready for Phase 3 clinical testing. Furthermore, during this period, it was promoted that the company's